PDCD1 and lung cancer: In recent years, as the detailed mechanism of tumor immunotherapy is understood, and anti PD-1 antibodies, one of the immune checkpoint inhibitors, have shown good results in clinical trials with increasing insurance support, the treatment of lung cancer has entered a new era.